Which has stronger earnings and valuation, CERS or RXST?

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.91 -$15.63M -$0.03 N/A RxSight $134.48M 2.13 -$38.94M -$1.13 N/A

Is CERS or RXST more profitable?

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% RxSight -36.80% -17.35% -14.70%

Does the media refer more to CERS or RXST?

In the previous week, RxSight had 8 more articles in the media than Cerus. MarketBeat recorded 11 mentions for RxSight and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat RxSight's score of 0.15 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RXST or SMTI more profitable?

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Sanara MedTech -29.15% 29.72% 2.84%

Does the media prefer RXST or SMTI?

In the previous week, RxSight had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 11 mentions for RxSight and 9 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.23 beat RxSight's score of 0.15 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to RXST or OSUR?

In the previous week, RxSight had 5 more articles in the media than OraSure Technologies. MarketBeat recorded 11 mentions for RxSight and 6 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.66 beat RxSight's score of 0.15 indicating that OraSure Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral OraSure Technologies 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend UTMD or RXST?

RxSight has a consensus target price of $8.37, indicating a potential upside of 21.43%. Given RxSight's higher possible upside, analysts clearly believe RxSight is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 RxSight 3 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.92

Does the media favor UTMD or RXST?

In the previous week, RxSight had 8 more articles in the media than Utah Medical Products. MarketBeat recorded 11 mentions for RxSight and 3 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.64 beat RxSight's score of 0.15 indicating that Utah Medical Products is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Utah Medical Products 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive RxSight 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, RXST or EMBC?

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $134.48M 2.13 -$38.94M -$1.13 N/A Embecta $1.08B 0.27 $95.40M $1.48 3.45

Is RXST or EMBC more profitable?

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Embecta 8.59% -19.25% 10.82%

Does the media prefer RXST or EMBC?

In the previous week, Embecta had 34 more articles in the media than RxSight. MarketBeat recorded 45 mentions for Embecta and 11 mentions for RxSight. Embecta's average media sentiment score of 0.32 beat RxSight's score of 0.15 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Embecta 4 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

RxSight (RXST) Competitors

$6.89 -0.12 (-1.71%)

Closing price 04:00 PM Eastern

Extended Trading

$6.90 +0.00 (+0.07%)

As of 07:22 PM Eastern

Compare

RXST vs. CERS, SMTI, OSUR, UTMD, and EMBC

Should you buy RxSight stock or one of its competitors? RxSight's main competitors and comparable companies include Cerus (CERS), Sanara MedTech (SMTI), OraSure Technologies (OSUR), Utah Medical Products (UTMD), and Embecta (EMBC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does RxSight compare to Cerus?

Cerus (NASDAQ:CERS) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
RxSight	-36.80%	-17.35%	-14.70%

In the previous week, RxSight had 8 more articles in the media than Cerus. MarketBeat recorded 11 mentions for RxSight and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat RxSight's score of 0.15 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.4% of Cerus shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 5.3% of Cerus shares are held by company insiders. Comparatively, 10.1% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.91	-$15.63M	-$0.03	N/A
RxSight	$134.48M	2.13	-$38.94M	-$1.13	N/A

Cerus has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, RxSight has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Cerus currently has a consensus price target of $4.00, indicating a potential upside of 34.23%. RxSight has a consensus price target of $8.37, indicating a potential upside of 21.43%. Given Cerus' stronger consensus rating and higher probable upside, research analysts clearly believe Cerus is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Summary

Cerus beats RxSight on 11 of the 15 factors compared between the two stocks.

How does RxSight compare to Sanara MedTech?

RxSight (NASDAQ:RXST) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

RxSight has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

RxSight presently has a consensus price target of $8.37, suggesting a potential upside of 21.43%. Sanara MedTech has a consensus price target of $35.00, suggesting a potential upside of 2.49%. Given RxSight's stronger consensus rating and higher possible upside, equities analysts plainly believe RxSight is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Sanara MedTech has lower revenue, but higher earnings than RxSight. Sanara MedTech is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.13	-$38.94M	-$1.13	N/A
Sanara MedTech	$103.12M	3.04	-$37.56M	-$3.77	N/A

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Sanara MedTech	-29.15%	29.72%	2.84%

78.8% of RxSight shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, RxSight had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 11 mentions for RxSight and 9 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.23 beat RxSight's score of 0.15 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

RxSight beats Sanara MedTech on 8 of the 15 factors compared between the two stocks.

How does RxSight compare to OraSure Technologies?

RxSight (NASDAQ:RXST) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

RxSight has a net margin of -36.80% compared to OraSure Technologies' net margin of -43.70%. RxSight's return on equity of -17.35% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
OraSure Technologies	-43.70%	-19.09%	-16.26%

78.8% of RxSight shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 4.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

RxSight has higher revenue and earnings than OraSure Technologies. RxSight is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.13	-$38.94M	-$1.13	N/A
OraSure Technologies	$115.02M	2.30	-$68.73M	-$0.69	N/A

In the previous week, RxSight had 5 more articles in the media than OraSure Technologies. MarketBeat recorded 11 mentions for RxSight and 6 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.66 beat RxSight's score of 0.15 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
OraSure Technologies	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

RxSight presently has a consensus price target of $8.37, indicating a potential upside of 21.43%. OraSure Technologies has a consensus price target of $3.00, indicating a potential downside of 21.88%. Given RxSight's stronger consensus rating and higher probable upside, equities research analysts clearly believe RxSight is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

RxSight has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

Summary

RxSight beats OraSure Technologies on 11 of the 16 factors compared between the two stocks.

How does RxSight compare to Utah Medical Products?

Utah Medical Products (NASDAQ:UTMD) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Utah Medical Products has higher earnings, but lower revenue than RxSight. RxSight is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Utah Medical Products	$38.52M	5.86	$11.29M	$3.28	21.65
RxSight	$134.48M	2.13	-$38.94M	-$1.13	N/A

Utah Medical Products has a net margin of 29.04% compared to RxSight's net margin of -36.80%. Utah Medical Products' return on equity of 8.74% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Utah Medical Products	29.04%	8.74%	8.50%
RxSight	-36.80%	-17.35%	-14.70%

Utah Medical Products has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, RxSight has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

In the previous week, RxSight had 8 more articles in the media than Utah Medical Products. MarketBeat recorded 11 mentions for RxSight and 3 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of 1.64 beat RxSight's score of 0.15 indicating that Utah Medical Products is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Utah Medical Products	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

RxSight has a consensus target price of $8.37, indicating a potential upside of 21.43%. Given RxSight's higher possible upside, analysts clearly believe RxSight is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

69.6% of Utah Medical Products shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 8.0% of Utah Medical Products shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Utah Medical Products beats RxSight on 9 of the 16 factors compared between the two stocks.

How does RxSight compare to Embecta?

RxSight (NASDAQ:RXST) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

RxSight currently has a consensus target price of $8.37, indicating a potential upside of 21.43%. Embecta has a consensus target price of $11.00, indicating a potential upside of 115.69%. Given Embecta's higher possible upside, analysts clearly believe Embecta is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Embecta	8.59%	-19.25%	10.82%

In the previous week, Embecta had 34 more articles in the media than RxSight. MarketBeat recorded 45 mentions for Embecta and 11 mentions for RxSight. Embecta's average media sentiment score of 0.32 beat RxSight's score of 0.15 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Embecta	4 Very Positive mention(s)	1 Positive mention(s)	33 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

RxSight has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Embecta has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.13	-$38.94M	-$1.13	N/A
Embecta	$1.08B	0.27	$95.40M	$1.48	3.45

78.8% of RxSight shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Embecta beats RxSight on 10 of the 16 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$291.57M	$5.95B	$7.06B	$13.10B
Dividend Yield	N/A	1.76%	2.57%	10.45%
P/E Ratio	-6.10	26.22	269.06	25.28
Price / Sales	2.13	63.09	602.43	91.76
Price / Cash	N/A	33.92	70.48	50.90
Price / Book	1.09	6.10	12.91	6.24
Net Income	-$38.94M	$148.67M	$3.45B	$347.60M
7 Day Performance	10.06%	1.84%	1.12%	1.07%
1 Month Performance	40.04%	4.56%	1.79%	1.03%
1 Year Performance	-16.18%	8.67%	67.69%	20.77%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXST RxSight	2.2247 of 5 stars	$6.89 -1.7%	$8.37 +21.4%	-15.6%	$291.57M	$134.48M	N/A	220
CERS Cerus	2.1028 of 5 stars	$2.12 -1.2%	$4.00 +88.3%	+113.5%	$422.18M	$206.13M	N/A	290
SMTI Sanara MedTech	1.5772 of 5 stars	$34.05 +0.1%	$35.00 +2.8%	+7.0%	$311.81M	$103.12M	N/A	60	Earnings Report Analyst Upgrade Short Interest Decrease
OSUR OraSure Technologies	1.83 of 5 stars	$4.09 -1.8%	$3.00 -26.6%	+41.1%	$280.63M	$115.02M	N/A	840
UTMD Utah Medical Products	2.2243 of 5 stars	$72.69 -0.1%	N/A	+21.4%	$231.15M	$38.52M	22.16	180	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors

RXST vs. CERS, SMTI, OSUR, UTMD, and EMBC

How does RxSight compare to Cerus?

Summary

How does RxSight compare to Sanara MedTech?

Summary

How does RxSight compare to OraSure Technologies?

Summary

How does RxSight compare to Utah Medical Products?

Summary

How does RxSight compare to Embecta?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RxSight (RXST) Competitors

RXST vs. CERS, SMTI, OSUR, UTMD, and EMBC

How does RxSight compare to Cerus?

Is CERS or RXST more profitable?

Does the media refer more to CERS or RXST?

Do institutionals and insiders have more ownership in CERS or RXST?

Which has stronger earnings and valuation, CERS or RXST?

Which has more volatility and risk, CERS or RXST?

Do analysts recommend CERS or RXST?

Summary

How does RxSight compare to Sanara MedTech?

Which has more volatility and risk, RXST or SMTI?

Do analysts prefer RXST or SMTI?

Which has preferable earnings & valuation, RXST or SMTI?

Is RXST or SMTI more profitable?

Do insiders & institutionals believe in RXST or SMTI?

Does the media prefer RXST or SMTI?

Summary

How does RxSight compare to OraSure Technologies?

Is RXST or OSUR more profitable?

Do insiders and institutionals have more ownership in RXST or OSUR?

Which has stronger valuation & earnings, RXST or OSUR?

Does the media refer more to RXST or OSUR?

Do analysts recommend RXST or OSUR?

Which has more volatility and risk, RXST or OSUR?

Summary

How does RxSight compare to Utah Medical Products?

Which has preferable earnings and valuation, UTMD or RXST?

Is UTMD or RXST more profitable?

Which has more volatility & risk, UTMD or RXST?

Does the media favor UTMD or RXST?

Do analysts recommend UTMD or RXST?

Do insiders & institutionals believe in UTMD or RXST?

Summary

How does RxSight compare to Embecta?

Do analysts recommend RXST or EMBC?

Is RXST or EMBC more profitable?

Does the media prefer RXST or EMBC?

Which has more risk & volatility, RXST or EMBC?

Which has better valuation & earnings, RXST or EMBC?

Do insiders and institutionals have more ownership in RXST or EMBC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools